A Sustained-Release Thermoplastic Polyurethane/Poly L-Lactide-Co-DL-Lactide (TPU/PLDLA) Cyclosporine-A Implant for the Treatment of Canine Keratoconjunctivitis Sicca: A Retrospective Case Series.

TPU/PLDLA cyclosporine implants show promise as alternative KCS treatment reducing application frequency.

This retrospective case series evaluated a sustained-release TPU/PLDLA polymer blend containing cyclosporine A as a subconjunctival implant for treating canine keratoconjunctivitis sicca (KCS). Seventeen dogs (27 eyes) with KCS refractory to topical cyclosporine or experiencing treatment challenges received the implant under sedation. Follow-up assessments at 1, 3, 6, and 9 months evaluated tear production (STT-1), conjunctival hyperemia, corneal pathology, and ocular discharge. The implant demonstrated good tolerability with significant reduction in conjunctival hyperemia by 3 months and ocular discharge by 9 months. Tear production increased in 19 eyes, though collective analysis showed no statistical significance. Three eyes showed no improvement, and two dogs with prior stem cell therapy did not achieve increased STT-1 levels. The TPU/PLDLA-CsA implant represents a promising alternative to frequent topical applications, offering sustained drug delivery with reduced treatment burden. However, the authors acknowledge limitations requiring larger sample sizes and extended follow-up periods to establish long-term efficacy, safety profiles, and optimal dosing protocols.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.